Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRI-AB trial
2024-520251-24-00Phase 4Authorised
- Sponsor
- University Hospital Odense
- Start
- Mar 2026
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of gentamicin, pivmecillinam, ampicillin and piperacillin + tazobactam in complicated urinary tract infection (cUTI) and acute pyelonephritis (3 arms), sponsored by University Hospital Odense. Primary endpoint: Clinical cure on day 3. Planned start Mar 2026; status: authorised.
02
Drugs
gentamicinpivmecillinamampicillinpiperacillin + tazobactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2024-520251-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520251-24-00.